S-ClassAbout S-Class
N
NUVBAI Stock Diagnostic Report
Nuvation Bio rises on FDA label update for Ibtrozi
[DEEPSEEK] Nuvation Bio's stock rose after the FDA approved a label update for its cancer treatment, Ibtrozi.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICE$5.78Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support5.63
Near-Term Resistance7.58
02
FUNDAMENTALS
Financial & Fundamental Analysis
Increased value of therapies for the indication through incorporation of clinical data and mitigation of regulatory risks.
03
TECHNICAL VIEW
Technical Position & Response Criteria
With the current price of $5.78 is near the 20-day low support line ($5.63), leaving room for a technical rebound, but volume participation should be monitored until the 20-day high resistance line ($7.58) is reached.
Support5.63
Resistance7.58
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
FDA의 Ibtrozi 보조 신약 신청(sNDA) 승인 및 중간 단계 임상 데이터 라벨 반영.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-09-17)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.